Nautilus Biotechnology Inc [NAUT] stock is trading at $1.82, up 5.81%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NAUT shares have gain 8.33% over the last week, with a monthly amount drifted -14.95%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nautilus Biotechnology Inc [NASDAQ: NAUT] stock has seen the most recent analyst activity on December 05, 2024, when Goldman downgraded its rating to a Sell but kept the price target unchanged to $1.75 for it. Previously, Guggenheim started tracking the stock with Buy rating on June 27, 2024, and set its price target to $6. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $8 on January 06, 2022. Cowen initiated its recommendation with a Outperform. Goldman started tracking with a Neutral rating for this stock on August 04, 2021, and assigned it a price target of $10. In a note dated July 13, 2021, Jefferies initiated an Buy rating and provided a target price of $13 on this stock.
Nautilus Biotechnology Inc [NAUT] stock has fluctuated between $1.61 and $3.25 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Nautilus Biotechnology Inc [NASDAQ: NAUT] shares were valued at $1.82 at the most recent close of the market. An investor can expect a potential return of 229.67% based on the average NAUT price forecast.
Analyzing the NAUT fundamentals
Gross Profit Margin for this corporation currently stands at 0.22% with Operating Profit Margin at -9.56%, Pretax Profit Margin comes in at -8.55%, and Net Profit Margin reading is -8.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.29 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7041 points at the first support level, and at 1.5883 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9129, and for the 2nd resistance point, it is at 2.0059.
Ratios To Look Out For
For context, Nautilus Biotechnology Inc’s Current Ratio is 16.65. As well, the Quick Ratio is 16.65, while the Cash Ratio is 0.51.
Transactions by insiders
Recent insider trading involved MARY GODWIN, Officer, that happened on Dec 17 ’24 when 38337.0 shares were purchased. Officer, MARY GODWIN completed a deal on Dec 09 ’24 to buy 35000.0 shares. Meanwhile, Officer MARY GODWIN bought 60000.0 shares on Dec 03 ’24.
